A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized, Phase III, multicenter, double-blinded, placebo-controlled study
designed to evaluate the safety and efficacy of ZKAB001 in combination with carboplatin +
etoposide compared with treatment with placebo + carboplatin + etoposide in patients who have
ES-SCLC and are untreated for their extensive-stage disease.